# Glaucoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/glaucoma

> 4 upcoming FDA catalysts in glaucoma: gen 2 travoprost intracameral implant (GKOS) on March 2028 (primary completion); gen 2 travoprost intracameral implant (GKOS) on Mar to Jun 2028 (topline data readout); gen 2 travoprost intracameral implant (GKOS) on June 2028 (primary completion); gen 2 travoprost intracameral implant (GKOS) on Jun to Sep 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 18, 2026 | [Bl1107 low dose primary completion](https://sec-api.dev/pdufa/bl1107) | BLCO | Glaucoma | completed | "NCT07168902 (Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-18 (ACTUAL); Lead Sponsor Bausch & Lomb Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07168902)) |
| March 2028 | [Gen 2 travoprost intracameral implant primary completion](https://sec-api.dev/pdufa/gen-2-travoprost-intracameral-implant) | GKOS | Glaucoma | scheduled | "NCT07075718 (Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Glaukos Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07075718)) |
| Mar to Jun 2028 | [Gen 2 travoprost intracameral implant topline data readout](https://sec-api.dev/pdufa/gen-2-travoprost-intracameral-implant) | GKOS | Glaucoma | scheduled | "NCT07075718 (Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Glaukos Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07075718)) |
| June 2028 | [Gen 2 travoprost intracameral implant primary completion](https://sec-api.dev/pdufa/gen-2-travoprost-intracameral-implant) | GKOS | Glaucoma | scheduled | "NCT07495852 (Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Glaukos Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07495852)) |
| Jun to Sep 2028 | [Gen 2 travoprost intracameral implant topline data readout](https://sec-api.dev/pdufa/gen-2-travoprost-intracameral-implant) | GKOS | Glaucoma | scheduled | "NCT07495852 (Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Glaukos Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07495852)) |

## Drugs

- [Bl1107 low dose](https://sec-api.dev/pdufa/bl1107) (BLCO)
- [Gen 2 travoprost intracameral implant](https://sec-api.dev/pdufa/gen-2-travoprost-intracameral-implant) (GKOS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/glaucoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Glaucoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/glaucoma

```bibtex
@misc{secapidev_indications_glaucoma_20261116,
  title        = {Glaucoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/glaucoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_glaucoma_20261116","title":"Glaucoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/glaucoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
